Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3–Directed and PSMA-Directed Bispecific Antibody–Drug Conjugate, for the Treatment of Prostate Cancer
- 1Institute of Research and Development, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
Abstract
Antibody–drug conjugate (ADC) has rapidly transformed the treatment landscape for solid tumors; however, owing to heterogeneity in target antigen expression, suboptimal efficacy and emergence of acquired resistance present significant challenges to the development of curative ADCs for cancers. In this study, we report the preclinical evaluation of GenSci143, a novel B7-H3 × PSMA-directed bispecific ADC, designed to overcome tumor antigen heterogeneity–associated drug resistance for the treatment of metastatic castration-resistant prostate cancer. GenSci143 comprises a highly active topoisomerase 1 inhibitor payload conjugated to a dual-targeting antibody via a plasma-stable linker to minimize off-target toxicity. Gene profiling analysis reveals high coexpression of B7-H3 and PSMA in prostate cancer, laying the biological basis of dual targeting strategy. In vitro, GenSci143 exhibited strong binding, efficient internalization, and potent cytotoxicity against prostate cancer cells expressing either or both target antigens, as well as a robust bystander killing effect, and outperformed single-target benchmark ADCs that are currently in clinical development. In multiple cancer cell line–derived and patient-derived xenograft models of prostate cancer, GenSci143 induced profound tumor regression and demonstrated superior antitumor activity versus competitor ADCs. Furthermore, GenSci143 displayed excellent plasma stability and favorable pharmacokinetic properties in nonhuman primates. The compelling preclinical efficacy across cancer models with varying levels of target antigen expression and its exceptional plasma stability support the translational relevance of GenSci143. These results indicate that GenSci143 is a promising therapeutic candidate for castration-resistant prostate cancer and potentially other malignancies, warranting its further clinical development.
Related
- Antibody-drug conjugate combination therapy targeting LGR5 and MET with different payloads enhances efficacy in preclinical colorectal cancer models
- Preclinical Evaluation of Bacterial Lysates in Murine Disease Models: A Systematic Review
- 257 Preclinical evaluation of in vivo CAR-T therapies using human PBMC and HSC reconstituted mouse models in Biocytogen
- 200 Preclinical evaluation of a tandem PD-L1/EphA2 CAR-T cell therapy in multiple solid tumor models
- Preclinical evaluation of a fully threaded biodegradable magnesium alloy headless compression screw for enhanced fixation in small bones
BibTeX
@article{xu2026molecular,
title = {{Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3–Directed and PSMA-Directed Bispecific Antibody–Drug Conjugate, for the Treatment of Prostate Cancer}},
author = {Yao Xu and Fu Li and Zhiyu Cui and Hongmei Xie and Liang Xu and Yihui Lin and Tete Li and Nan Li and Dechen Cao and Weiming He and Wenqiang Zhai and Xiaozhen Wang and Shu Zhang and Haizhou Zhang and Fanglong Yang and Siqin Wang and Lei Jin and John L. Xu},
journal = {Molecular Cancer Therapeutics},
year = {2026},
month = may,
doi = {10.1158/1535-7163.mct-26-0395},
url = {https://doi.org/10.1158/1535-7163.mct-26-0395},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3–Directed and PSMA-Directed Bispecific Antibody–Drug Conjugate, for the Treatment of Prostate Cancer
AU - Yao Xu
AU - Fu Li
AU - Zhiyu Cui
AU - Hongmei Xie
AU - Liang Xu
AU - Yihui Lin
AU - Tete Li
AU - Nan Li
AU - Dechen Cao
AU - Weiming He
AU - Wenqiang Zhai
AU - Xiaozhen Wang
AU - Shu Zhang
AU - Haizhou Zhang
AU - Fanglong Yang
AU - Siqin Wang
AU - Lei Jin
AU - John L. Xu
PY - 2026
DA - 2026/05/29
JO - Molecular Cancer Therapeutics
DO - 10.1158/1535-7163.mct-26-0395
UR - https://doi.org/10.1158/1535-7163.mct-26-0395
AB - Antibody–drug conjugate (ADC) has rapidly transformed the treatment landscape for solid tumors; however, owing to heterogeneity in target antigen expression, suboptimal efficacy and emergence of acquired resistance present significant challenges to the development of curative ADCs for cancers. In this study, we report the preclinical evaluation of GenSci143, a novel B7-H3 × PSMA-directed bispecific ADC, designed to overcome tumor antigen heterogeneity–associated drug resistance for the treatment of metastatic castration-resistant prostate cancer. GenSci143 comprises a highly active topoisomerase 1 inhibitor payload conjugated to a dual-targeting antibody via a plasma-stable linker to minimize off-target toxicity. Gene profiling analysis reveals high coexpression of B7-H3 and PSMA in prostate cancer, laying the biological basis of dual targeting strategy. In vitro, GenSci143 exhibited strong binding, efficient internalization, and potent cytotoxicity against prostate cancer cells expressing either or both target antigens, as well as a robust bystander killing effect, and outperformed single-target benchmark ADCs that are currently in clinical development. In multiple cancer cell line–derived and patient-derived xenograft models of prostate cancer, GenSci143 induced profound tumor regression and demonstrated superior antitumor activity versus competitor ADCs. Furthermore, GenSci143 displayed excellent plasma stability and favorable pharmacokinetic properties in nonhuman primates. The compelling preclinical efficacy across cancer models with varying levels of target antigen expression and its exceptional plasma stability support the translational relevance of GenSci143. These results indicate that GenSci143 is a promising therapeutic candidate for castration-resistant prostate cancer and potentially other malignancies, warranting its further clinical development.
SN - 1535-7163
SN - 1538-8514
ER -